Access Broad B Cell Diversity to Select Better Antibody Lead Candidates in Just Days.

With Berkeley Lights’ technology and platforms, discover hundreds of functional leads in just one day. Surpass the limitations of other methods.

Antibody discovery

 

Greater B Cell Diversity

Discover Thousands of Hits in Days, Not Months

 

AbD chip workflow

 

Plasma B discovery on the Beacon platform enables automated, direct screening of B cells immediately after organ harvest and cell purification. B cells can be screened from multiple organs (spleen, bone marrow, lymph nodes) and cultured for multiple days in specialized media to enable repeated screens from a single cell sample.

Rapid Screening of the B Cell Repertoire

Plasma B Discovery on the Beacon Platform Enables Rapid Screening of the B Cell Repertoire Without Time-Consuming and Inefficient Hybridoma Fusion.

 

Hybridoma Workflow

 

Link Sequence with Function in Just Two Days

Every antibody sequence can be mapped directly to a known antibody function. Sequence relationships identify individual mutations that confer antigen specificity, cross-reactivity, and function.

 

Chip zoom-in

Down-Select Lead Candidates Earlier

The beacon enables downselection of lead candidates through multiple assays for antigen specificity and function. Nanopen™ chambers enable rapid, precise and highly sensitive assays.

With a NanoPen™ volume of only 250 picoliters, reactions are fast and precise. Assays complete in less than 1 hour, and chips can then be reset to enable the next assay to begin. Better characterization upfront reduces the expense of having to sequence or clone irrelevant non-functional hits.

antigen
FUNCTIONAL ASSAY

antigen
LIGAND BLOCKING ASSAY

antigen
CROSS-SPECIES ASSAY

antigen
ANTIGEN SPECIFIC BEAD ASSAY

Plasma B Cell Screening

OUR OPTOSELECT™ CHIPS CAN SCREEN THOUSANDS OF PLASMA B CELLS AT THE SAME TIME.

With the Beacon plasma B cell workflow, everything you need to connect antibody function to gene sequence at the single-cell level is available. Increase your chances of finding rare functional antibodies (e.g., 0.01% of the plasma B cell repertoire).

circle image chart
Rich CDR3 diversity of >650 antigen-specific antibody sequences obtained in less than 1 week.